Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Concordance Study of CD30 Expression Detected by Multiple Immunohistochemistry Assays and VENTANA CD30 Assay in Chinese Lymphoma Patients

NCT05288491 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT05288491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05288491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Concordance Study of CD30 Expression Detected by Multiple Immunohistochemistry Assays and VENTANA CD30 Assay in Chinese Lymphoma Patients
Lead sponsor
Takeda
Phase
Observational
Overall status
Completed
Start date
October 31, 2022
Completion date
June 20, 2024
Enrollment
934 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma